مؤسسة الشرق الأوسط للنشر العلمي
عادةً ما يتم الرد في غضون خمس دقائق
Medulloblastoma, is a high-grade paediatric tumour of the brain which is created in the posterior fossa mostly. It includes multiple fields such as risk factors, incidence, pathogenesis, clinical features, diagnostic techniques, therapy, and prognosis. Through a synopsis of ongoing research, the paper will be aimed to promote knowledge and increase the chance of better treatment for children who have this defect. Objective :The goal of this paper is to look into maximum extensively Medulloblastoma, from its molecular mechanism to clinical treatment. that evidenced the existence of such carriers and established their regulating roles in medulloblastoma biology. Material and methods Patients with age varying from 3-21 years were divided into two groups: low level of risk and high level of risk. Hierarchy was used based on the extent of metastasis and the degree of resection. Medulloblastomas were molecularly classified into subgroups (WNT , SHH ), and subtypes were made based on DNA modifications by methyl sequencing combined with mutation data obtained by next generation sequencing. The primary endpoints explored were (1) the correlation between tumor-based expression of ERBB2 and progression-free survival (PFS); and (2), the frequency of mutations related to WNT and SHH tumors. In relation to molecular and clinical risk factors, the features with the highest robustness were modelled and used for the risk classification. Histopathological Examination as in Fig(3,4)were performed on formalin-fixed, paraffin-embedded (FFPE) tumor samples. Hematoxylin and eosin (H&E) staining were used to evaluate tumor morphology .